Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD

By afschroeder • May 28, 2026

Piotrowska Z, Goldberg SB, Goldman JW, de Langen AJ, Le X, Okamoto I, Riess JW, Yu HA, Nishino K, Novello S, Ponce S, Ambrose H, Smith PE, Tang KH, Lehman JM, Cho BC. Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD. Eur J Cancer. 2026 May 18;242:116807. doi: 10.1016/j.ejca.2026.116807. Epub ahead of print. PMID: 42202477.

Tags: BRAF, EGFR, Hematology/Oncology, NSCLC, Osimertinib, Publications, Selumetinib

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer

Sayar E, Richards HM, Gulati R, Patel RA, Hanratty B, Lee HJ, Coleman I, Mustafi P, Ding CC, Chen WS, Quigley D, Setty M, Lang[...]

Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies

Maron SB, Xu RH, Wainberg ZA, Rha SY, Zhang Y, Pietrantonio F, Oliveira SCS, Li Y, Chen MH, Korphaisarn K, Elimova E, Calderon CA, Herpe[...]

Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249

Kuroki LM, Enserro DM, Lankes HA, Strickland KC, Previs R, Clements A, Powell MA, Klopp A, Ratner E, DiSilvestro P, Cosgrove C, Cantuaria GH, Spirtos[...]